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Abstract
Background: Genetic testing has potential roles in identifying whether an individual would have risk of adverse
drug reactions (ADRs) from a particular medicine. Robust cost-effectiveness results on genetic testing would be
useful for clinical practice and policy decision-making on allocating resources effectively. This study aimed to
update a systematic review on economic evaluations of pharmacogenetic testing to prevent ADRs and critically
appraise the quality of reporting and sources of evidence for model input parameters.
Methods: We searched studies through Medline via PubMed, Scopus and CRD’s NHS Economic Evaluation up to
October 2019. Studies investigating polymorphism-based pharmacogenetic testing, which guided drug therapies to
prevent ADRs, using economic evaluation methods were included. Two reviewers independently performed data
extraction and assessed the quality of reporting using the Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) guidelines and the quality of data sources using the hierarchy of evidence developed by
Cooper et al.
Results: Fifty-nine economic evaluations of pharmacogenetic testing to avoid drug-induced ADRs were found
between 2002 and 2018. Cost-utility and cost-effectiveness analyses were the most common methods of economic
evaluation of pharmacogenetic testing. Most studies complied with the CHEERS checklist, except for single study-
based economic evaluations which did not report uncertainty analysis (78%). There was a lack of high-quality
evidence not only for estimating the clinical effectiveness of pharmacogenetic testing, but also baseline clinical
data. About 14% of the studies obtained clinical effectiveness data of testing from a meta-analysis of case-control
studies with direct comparison, which was not listed in the hierarchy of evidence used.
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Conclusions: Our review suggested that future single study-based economic evaluations of pharmacogenetic
testing should report uncertainty analysis, as this could significantly affect the robustness of economic evaluation
results. A specific ranking system for the quality of evidence is needed for the economic evaluation of
pharmacogenetic testing of ADRs. Differences in parameters, methods and outcomes across studies, as well as
population-level and system-level differences, may lead to the difficulty of comparing cost-effectiveness results
across countries.
Keywords: Pharmacogenomics, Adverse drug reactions, Economic-evaluation, Systematic review, Personalized
medicine
Background
In the United States (US), adverse drug reactions (ADRs)
are the fourth to the sixth leading cause of death, with
approximately more than 100,000 deaths per year [1].
Besides this, there is a similar trend in Europe, with ap-
proximately 5% of all hospitalizations and 197,000
deaths annually reported [2, 3]. The most severe life-
threatening ADRs are the Stevens-Johnson syndrome
(SJS) and toxic epidermal necrolysis (TEN). The majority
of cases are caused by reactions to certain drugs, e.g.,
allopurinol, sulfa-drugs or carbamazepine. Moreover,
ADRs could result in substantial economic burden. The
annual economic impact of severe and fatal ADRs lead-
ing to mortality and morbidity was found to be excep-
tionally high, totaling nearly $177 billion in the US and
€79 billion in Europe [2, 4].
Nowadays, there are several methods for investigating
people who are at risk of ADRs according to clinical fea-
tures, such as renal or liver function, age, dosage of ad-
ministration, as well as identification of any drug
interaction. Genetic factors can also be the cause of
ADRs, which accounted for approximately 10–20% [5].
Genetic information obtained from polymorphism-based
pharmacogenomics or pharmacogenetics is highly cru-
cial to better identifying responders and non-responders
to medications, as well as people who are at risk of
ADRs or drug inefficacy prior to prescription [6]. More-
over, there has been an increasing number of genetic as-
sociations to develop clinically useful tests through
international guidelines, including the Clinical Pharma-
cogenetics Implementation Consortium (CPIC), the
Royal Dutch Association for the Advancement of Phar-
macy - Pharmacogenetics Working Group (DPWG) and
the Canadian Pharmacogenomics Network for Drug
Safety (CPNDS).
The CPIC has developed guidelines on evidence-based
pharmacogenetic testing for 54 drugs-gene pairs, which
supported and guided the translation of clinically rele-
vant aspect. In addition to this, pharmacogenetics-based
therapeutic recommendations for 94 and 8 drugs-gene
pairs were published by DPWG and the CPNDS, re-
spectively [7]. It is important to note that the application
of pharmacogenetic information before prescribing the
corresponding medication is beneficial to avoid serious
ADRs or to guide genotype-specific dosing, thereby en-
hancing the effective use of drug treatment. Therefore,
national drug agencies have approved drug labels con-
taining pharmacogenetic information. As of August 1,
2020, 335, 134, 105 and 52 drug labels were approved by
the United States Food and Drug Administration (US
FDA), the European Medicines Agency (EMA), the US
Health Care Service Corporation (HCSC) and the Phar-
maceuticals and Medical Devices Agency (PMDA) of
Japan, respectively [6, 7].
Currently, the most important criteria for its imple-
mentation in clinical practice is not only clinical evi-
dence of pharmacogenetic testing, but also its value for
money, which can be proved by an economic evaluation
being a vital tool used to inform resource allocation in
the decision-making process, especially in developed
countries [8, 9]. Therefore, the quality of methodological
rigor in cost-effectiveness studies is required to increase
the reliability of such studies. Until now, there were two
systematic reviews specifically focusing on economic
evaluation of pharmacogenetic testing to prevent ADRs
[10, 11]. The first review published in 2008, [10] was
aimed at determining the cost of thiopurine methyl-
transferase (TPMT) genotyping per averted case of neu-
tropenia. It did not, however, evaluate the quality of
included studies. Later in 2016, another review, [11]
which included all studies up to 2015, assessed the qual-
ity of studies in terms of their reporting and evidence of
clinical effectiveness of testing but did not include other
parameters. Notably, it has been suggested that the
sources of evidence for clinical effectiveness, baseline
clinical value, resource utilization, cost and utility data,
all of which can influence and contribute to biased esti-
mates of economic evaluation results, should be taken
into account [12].
Therefore, this review aimed to update a systematic re-
view and critically appraise the quality of existing eco-
nomic evaluations of pharmacogenetic testing to prevent
ADRs, in terms of reporting and sources of evidence
used for all significant model inputs, such as clinical ef-
fectiveness, baseline clinical data, resource use, cost and
utilities. Due to methodological differences across
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studies, as well as population-level and system-level
differences, our findings could assist in identifying the
potential model parameters that could influence the
cost-effectiveness results and their transferability across
geographic regions. They could also be valuable in a
future and robust cost-effectiveness analysis of pharma-
cogenetic testing to prevent ADRs, which might help
policy-makers make better decisions on allocating re-
sources effectively and implement such testing into
clinical practice.
Methods
A systematic review protocol was initially registered
with PROSPERO, an international prospective registry
of systematic reviews (identification number
CRD42019142060) and available from: http://www.
crd.york.ac.uk/PROSPERO/display_record.php?ID=
CRD42019142060. The present systematic review was
conducted in accordance with the guidelines of the
Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) [13].
Identification of studies
We conducted a systematic search in Medline (via
PubMed), Scopus and the Centre for Reviews and Dis-
semination (CRD)‘s National Health Service Economic
Evaluation Database (NHS EED) to identify relevant
studies up to October 2019. The search terms were con-
structed based on the PICOS domains (patient, interven-
tion, comparison, outcome and study type). The search
terms were comprised of the domains on the interven-
tion (pharmacogenetic testing and ADRs) and study type
(economic evaluation). There were no restrictions in the
domains of patients, comparators and outcomes. The
search terms were explicitly used for each search engine
and search strategies for each database, as stated in the
online appendices (Electronic Supplementary Mater-
ial) Table A1. The reference lists of the retrieved studies
were also explored to identify further studies. The search
was updated every six months.
Selection of studies
Two reviewers (ST and OR) independently selected
studies by screening titles and abstracts of all articles
based on the eligibility criteria. Full texts of articles iden-
tified in the initial screening were retrieved. The studies
were included if they met all of the following criteria.
First, studies were included if they investigated pharma-
cogenetic testing of human genetic variations, which
guided drug therapies to prevent ADRs. Second, the
study type was an economic evaluation, e.g., cost-
effectiveness analysis (CEA), cost-utility analysis (CUA),
cost-benefit analysis (CBA) or cost-minimization analysis
(CMA). Studies were excluded if the drug and
pharmacogenetic testing were not on the list of the
available clinical practice guidelines (e.g., CPIC, DPWG,
CPNDS), or if the prescribing information for labelling
was not approved by the US FDA as of August 1, 2020.
Any disagreements were resolved through discussion.
Data extraction
Data were extracted independently by two authors (ST
and OR) using a data extraction form, which included
the study characteristics, author, year of publication, set-
ting, target populations, intervention, comparator,
marker frequency, methods, perspective, time horizon,
discounting, uncertainty analysis, and outcome mea-
sures, in terms of incremental cost, incremental cost per
quality adjusted life year (QALY) or life year (LY) gained
or cost per adverse reaction/event avoided. We also
gathered the parameters, which may affect the cost-
effectiveness results according to the uncertainty analysis
results of individual studies.
Quality assessment of economic evaluation reporting
The quality of economic evaluation reporting was ap-
praised using the Consolidated Health Economic Evalu-
ation Reporting Standards (CHEERS) checklist with 24
items [14]. Two independent authors (ST and OR)
assessed the quality of reporting and any disagreements
were resolved through discussion. A percentage of agree-
ment and disagreement by checklist item was calculated.
We evaluated the quality of reporting along with the
CHEERS checklist by rating scores as follows: the study
met all standards (score = 1), the study met some stan-
dards (score = 0.5), the study did not meet the standards
(score = 0), or the study was not applicable (N/A). For
instance, in the checklist item indicating whether the
study reported time horizon and described its appropri-
ateness, a score of 1, 0.5 and 0 will be given if the au-
thors met all standards (i.e., they reported both the time
horizon and reason why it was appropriate), if they met
some standards (i.e., they reported either the time hori-
zon or description of its appropriateness), and if they did
not meet the standards (i.e., failed to report both).
Quality assessment of evidence used
The quality of evidence for input parameters used in
economic evaluations, such as clinical effect sizes, base-
line clinical data, resource use, costs and utilities (for
cost-utility analyses) was assessed using the hierarchy of
data sources developed by Cooper et al. [12]. Each item
was evaluated and given a rank ranging from 1 to 6, and
9 was applied to a source which was not clear. For ex-
ample, for parameters related to clinical effect sizes, rank
1+ or 1 was given if the data were obtained from a
meta-analysis of randomized controlled trials (RCTs) or
single RCT with direct comparison measuring final
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outcomes, respectively. Other rates included: rank 2 (a
single RCT with direct comparison measuring surrogate
outcomes), rank 3 (a single placebo RCTs measuring
surrogate outcomes), rank 4 (case control or cohort
studies), rank 5 (case report or case series) and rank 6
(expert opinion). Two authors (ST and OR) independ-
ently assessed and ranked data sources of the input pa-
rameters based on the hierarchy of data sources
published by Cooper et al. [12]. Any disagreements were
resolved through discussion and a percentage of agree-
ment and disagreement by input parameter was
calculated.
Transferability assessment of economic evaluation studies
We applied the transferability method developed by
Welte et al. [15] to identify potential transferability fac-
tors across countries, which can be categorized into
three groups: (1) methodology (i.e., perspective, time
horizon, cost categories, and discount rate) (2) health-
care system (i.e., practice variation and technology avail-
ability), and (3) population characteristics (i.e., disease
incidence/prevalence, life expectancy, acceptance and
compliance). Based on our review, economic evaluation
studies of pharmacogenetic testing conducted across
countries were selected as a case-study to assess whether
different transferability factors could directly affect the




A total of 6718 studies were searched from Medline
(1544 studies), Scopus (3010 studies) and Cochrane
Database of Systematic Reviews (CDSR) (2164 studies).
After excluding 816 duplicates, 5902 studies were
screened for titles and abstracts. From these, 5824 stud-
ies were excluded for several reasons. The most com-
mon reasons were “non-genetic interventions” and “non-
drug-related ADRs”, as described in Fig. 1. A total of 64
studies met the inclusion criteria. Nevertheless, five
studies were excluded since they were not included in
the list of available clinical practice guidelines. Finally,
59 studies were eligible for data extraction.
Characteristics of the included studies
The general characteristics of all included studies are
presented in online appendices (Electronic Supple-
mentary Material) Table A2. All studies were published
between 2002 and 2018. CUA was the most frequent
type of economic evaluation (41 studies) (70%), followed
by CEA (10 studies) (17%), CBA (5 studies) (8%), and
then CMA (3 studies) (5%). Table 1 demonstrates the
number of studies categorized by therapeutic area-gene
and ADRs, as well as by region. Majority of the studies
were conducted in European and American countries
(43 studies) (73%), while studies related to HLA-B*58:01-
allopurinol and HLA-B*15:02-carbamazepine were
mostly found in Asian countries. Most studies investi-
gated the therapeutic area of cardiovascular diseases (24
studies) [16–39], followed by gout (8 studies) [40–47],
human immunodeficiency virus (HIV) infection (8 stud-
ies) [48–55], autoimmune diseases (8 studies) [56–63],
and epilepsy/neuropathic pain (6 studies) [64–69], can-
cer (3 studies) [70–72], major depressive disorder [73],
and hormone replacement therapy [74].
The majority of pharmacogenetic testing to prevent
ADRs were CYP2C9 and VKORC1 testing before pre-
scription of warfarin (14 studies) [16–29], CYP2C19
genotype screening for selection of antiplatelet therapy
(i.e., clopidogrel) after percutaneous coronary interven-
tion (PCI) for acute coronary syndrome (ACS) patients
(9 studies) [30–38], and HLA-B*58:01 screening before
prescribing allopurinol in patients with gout (8 studies)
[40–47]. Moreover, the severity of ADRs related to
gene-drug pairs was grouped into two major types: se-
vere ADRs (life-threatening or fatal ADRs) and common
ADRs. Pharmacogenetic testing and drugs associated
with severe ADRs were HLA-B*58:01-allopurinol in-
duced SJS/TEN/drug reaction with eosinophilia and sys-
temic symptoms (DRESS), HLA-B*57:01-abacavir
induced hypersensitivity reaction, HLA-B*15:02 and
HLA-A*31:01- carbamazepine induced SJS/TEN/hyper-
sensitivity, TPMT-azathioprine induced severe bone
marrow toxicity, UGT1A1- irinotecan induced severe
neutropenia and DPYD- fluoropyrimidines induced se-
vere hematologic/GI toxicity. Meanwhile, the others
were pharmacogenetic testing and drug-associated com-
mon ADRs. Most of the genetic information regarding
gene-drug pairs was published by the CPIC guideline
[75] and drug labels were approved by the US FDA, ex-
cept for the study determining Factor V Leiden screen-
ing before receiving estrogen combined with oral
contraceptives [76].
Quality assessment of economic evaluation reporting
using the CHEERS checklist
The quality of economic evaluation reporting using the
CHEERS checklist [14] is summarized in online appen-
dices (Electronic Supplementary Material) Table A3.
All included studies clearly described the study popula-
tion, measurement of effectiveness based on single study
or synthesis estimated, as well as approaches for estimat-
ing resource use and costs with the percentage of agree-
ment between two independent authors ranging from 81
to 100%, indicating that the score rating for each item
was reliable. In contrast, only 22% of the single (trial)
study-based performed uncertainty analysis of the pa-
rameters and evaluated their effects, as detailed in
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Table 2. Notably, 18 studies (31%) adopted a health
service or healthcare payer’s viewpoint in the analysis,
while 10 studies (17%) and 9 studies (15%) presented
societal and healthcare system’s perspectives, respect-
ively. There were nine studies (15%) that did not
mention the study’s perspective [27, 28, 32, 41, 49,
57, 59, 66, 74]. The time horizon used for cost and
consequence evaluation ranging from six weeks to a
lifetime was also reported in the above studies, while
five studies (8%) did not state the time horizon [32,
48, 61, 66, 70]. Among the studies that specified a
time horizon exceeding one year, there were seven
studies (18%) that did not report the discount rate for
costs and outcomes [32, 39, 48, 49, 61, 66, 70].
For clinical effectiveness data, 50 studies (85%) used a
single, study-based estimate and nine studies (15%) used
synthesis-based estimates. All studies clearly described
the source of evidence. Most studies (50 studies; 85%)
were conducted based on the decision-analytic model,
while nine studies (15%) used a single study-based eco-
nomic evaluation. Seven studies (78%) including retro-
spective, observational, or RCT-based economic
evaluations studies did not mention uncertainty analysis
[27, 32, 41, 48, 59, 61, 66] as they did not indicate confi-
dence intervals denoting uncertainty measures. However,
all model-based economic evaluations performed uncer-
tainty analysis. More than half (26 of 50 model-based
studies; 52%), performed both one-way sensitivity ana-
lysis and probabilistic sensitivity analysis (PSA), while
some conducted the one-way sensitivity analysis only (6
studies; 12%) and PSA only (6 studies; 12%). There were
12 studies (20%) and 13 studies (22%) that did not de-
scribe any source of funding [21, 28, 40, 41, 48, 51, 54,
57, 59–62] and the potential for conflict of interest of
study contributors [29, 37, 43, 45, 52, 54, 57, 59–61, 63,
71, 74], respectively.
Quality assessment of evidence used
Only 16 studies (27%) obtained clinical effectiveness data
of testing from high-quality evidence (a single RCT with
direct comparison, rank 1), while about half (49%) re-
trieved evidence from case-control or cohort studies
(rank 4). Nevertheless, 8 studies (14%) used clinical ef-
fectiveness data of testing from the meta-analysis of
Fig. 1 PRISMA flow of study selection process
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case-control study with direct comparison, which was
not listed in the hierarchy of data sources by Cooper
et al. [12]. Moreover, only four (7%) and one studies
(2%) applied the baseline clinical data from a high-
quality evidence [case series specifically performed for
the study (rank 1) and the analysis of administrative da-
tabases including only patients in interested settings
(rank 2)]; whereas most studies (85%) obtained clinical
effectiveness data of testing from old case series, analysis
of reliable administrative databases, or estimated from
RCTs (rank 4). On the other hand, most studies sourced
resource use and cost information from a high-quality
evidence [prospective data analysis conducted for
specific study (rank 1) or recently published cost estima-
tion based on reliable databases (rank 2)], except for one
study on HLA-B*57:01-abacavir, which used data from
expert opinions (rank 6) [52]. For CUA studies, the util-
ity data were mostly (93%) estimated from a direct utility
from a previous study in patients with the disease of
interest (rank 3). Only one study for CYP2B6-efavirenz
did not define the data source (rank 4) [53]. However,
there was no evidence obtained from indirect utility or
expert opinion. Overall, the percentage of agreement be-
tween two independent authors ranging from 81 to 97%,
suggesting that the ranking of data sources was reliable,
see Table 3.
Table 1 Number of studies classified by therapeutic area-gene and ADRs and by region





Number of studies by
region








bleeding NS CPIC, DPWG,
CPNDS
√ 2 12 14
Clopidogrel CYP2C19 major cardiac/adverse
CV events
NS CPIC,DPWG √ 1 8 9
Statins Pharmacogenetics
test
myopathy NS CPIC, DPWG √ – 1 1
Gout (8)
Allopurinol HLA-B*58:01 SJS/TEN, DRESS S CPIC √ 6 2 8
HIV infection (8)
Abacavir HLA-B*57:01 Hypersensitivity S CPIC, DPWG √ 1 6 7
Efavirenz CYP2B6 CNS toxicity NS CPIC,DPWG √ – 1 1
Autoimmune disease (8)
Azathioprine TPMT severe bone marrow
toxicity
S CPIC, DPWG √ 1 7 8
Epilepsy/neuropathic pain (6)
Carbamazepine HLA-B*15:02 SJS/TEN S CPIC, CPNDS √ 5 – 5
Carbamazepine HLA-A*31:01 SJS/TEN,
Hypersensitivity
S CPIC, CPNDS √ – 1 1
Cancer (3)
Irinotecan UGT1A1 severe neutropenia S DPWG √ – 2 2
Fluoropyrimidines DPYD severe hematologic,
GI toxicity
S CPIC, DPWG √ – 1 1
Major depressive disorder (1)
Nortriptyline CYP2D6 anticholinergic
symptoms
NS CPIC, DPWG √ – 1 1
Hormone replacement therapy (1)
Estrogen combined in oral
contraceptives
Factor V Leiden venous
thromboembolic
disease
NS DPWG – – 1 1
CBA: cost-benefit analysis, CEA: cost-effectiveness, CMA: cost-minimization analysis, CUA: cost-utility analysis, CPIC: the Clinical Pharmacogenetics
Implementation Consortium, CPNDS: the Canadian Pharmacogenomics Network for Drug Safety, DPWG: the Royal Dutch Association for the Advancement of
Pharmacy - Pharmacogenetics Working Group, DRESS: drug reaction with eosinophilia and symptomatic symptoms, FDA: the United States Food and Drug
Administration, NS: Non-Severe ADRs, S: Severe ADRs, SJS: Stevens-Johnson syndrome, TEN: toxic epidermal necrolysis
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Cost-effectiveness results
In terms of pharmacogenetic testing and drugs associ-
ated with ADRs in particular disease areas, such as car-
diovascular diseases, gout, HIV infection, autoimmune
diseases, epilepsy/neuropathic pain, cancer, major de-
pressive disorder, and hormone replacement therapy, the
results of economic evaluation studies are summarized
and presented in Table 4.
Cardiovascular diseases
CYP2C9 and VKORC1 and warfarin-induced risk of
bleeding There were 14 economic evaluation studies of
CYP2C9 and VKORC1 testing before prescription of
warfarin to prevent risks of bleeding. Over the prior
from 2004 to 2017, these studies were conducted in
Korea (1 study) [16], UK and Sweden (1 study) [17],
Croatia (1 study) [18], Thailand (1 study) [21], Sweden
(1 study) [20], Netherlands [28] and US (8 studies) [19,
22–27, 29]. Ten studies were CUA with model-based
economic evaluation [16–19, 21–26] and another study
was CUA with a trial-based [20] economic evaluation to
estimate resource use associated with the interventions.
Two studies were CEA with model-based [28, 29] and
one study was CEA based on a retrospective study [27].
Seven studies were explicitly conducted in patients with
atrial fibrillation and one study investigated mechanical
heart valve replacement (MHVR). The rest of the studies
were used in newly initiated warfarin therapy. Nine stud-
ies showed that CYP2C9 and VKORC1 testing to prevent
the risk of bleeding would be a cost-effective interven-
tion [16–20, 22, 27–29] (i.e., less costly and more effect-
ive than treatment without genotyping). One study
suggested that testing would be cost-effective if it in-
creased the time spent in the target international nor-
malized ratio (INR) range during the first three months
of treatment by 5 to 9% [25]. Nevertheless, four studies
from Thailand [21] and US [23, 24, 26] suggested that
those testings would not be cost-effective due to the ef-
fectiveness of testing in reducing out-of-range INR
values.
CYP2C19 and clopidogrel-induced major adverse
cardiovascular events (MACE) There were nine studies
which conducted an economic evaluation of CYP2C19
testing before prescription of clopidogrel to avoid car-
diovascular events in patients with ACS undergoing PCI.
They were performed in Hong Kong (1 study) [30],
Table 2 Quality assessment results of economic evaluation reporting using the CHEERS checklist





Target population and subgroups (4) 59/59 100 98
Study perspective (6) 50/59 85 81
Comparators (7) 58/59 98 98
Time horizon (8) 54/59 92 98
Discount rate for costs and outcomes (9) †† 32/39 82 86
Measurement of effectiveness (Single study-based estimates)
(11a)#
50/50 100 95
Measurement of effectiveness (Synthesis-based estimates) (11b)
##
9/9 100 95
Estimating resources and costs (Single study-based EE) (13a)* 9/9 100 95
Estimating resources and costs (Model-based EE) (13b)** 50/50 100 95
Study parameters (18) 50/59 85 84
Incremental costs and outcomes (19) 57/59 97 95
Characterizing uncertainty (Single study-based EE) (20a)* 2/9 22 98
Characterizing uncertainty (Model-based EE) (20b)** 50/50 100 100
Source of funding (23) 47/59 80 95
Conflicts of interest (24) 46/59 78 97
EE: Economic evaluation
† Percent agreement between two independent raters
†† The denominator for the calculations is the studies that reported the discount rate for costs and/or outcomes were from a study period longer than one year,
including 39 studies
# The denominator for the calculations is a single study-based estimate of clinical effectiveness data, including 50 studies
## The denominator for the calculations is synthesis-based estimates of clinical effectiveness data, including 9 studies
* The denominator for the calculations is a single study-based economic evaluation, including 9 studies
** The denominator for the calculations is a single model-based economic evaluation, including 50 studies
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Netherlands (1 study) [32], Australia (1 study) [35], New
Zealand (1 study) [38] and US (5 study) [31, 33, 34, 36,
37]. They were conducted from 2012 to 2018. Seven
studies were CUA with model-based approach [30, 31,
33–36, 38] and one study was CUA with trial-based [32]
Others were CEA with model-based [37] economic
evaluation. All studies showed that CYP2C19 testing
would be a potentially cost-effective treatment strategy
for avoiding MACE. Nevertheless, some studies consid-
ered ticagrelor and/or prasugrel as alternative drugs with
a higher cost than clopidogrel for those who tested
positive.
Pharmacogenetic testing and statin-induced
myopathy One study developed testing that identified
statin-induced myopathy in cardiovascular patients by
using CUA with model-based economic evaluation in
2017. The results demonstrated that genotyping would
be a cost-effective intervention, with a testing cost of
CAN$ 906 that was less than the cost of no testing in
Canada [39].
Gout
HLA-B*58:01 and allopurinol-induced SJS/TEN and
DRESS There were eight economic evaluation studies of
HLA-B*58:01 screening before prescribing allopurinol in
gout patients to prevent SJS/TEN and DRESS) that were
performed in China (1 study) [41], Malaysia (1 study)
[40], US (1 study) [44], Taiwan (1 study) [43], UK (1
study) [42], Singapore (1 study) [46], Korea (1 study)
[45], and Thailand (1 study) [47] from 2014 to 2018. Six
studies used CUA with model-based economic evalu-
ation [40, 42–44, 46, 47]), one performed CMA with
trial-based [41] and one conducted CBA with model-
based approach [45]. All studies were conducted in pa-
tients with gout, and two studies were explicitly con-
ducted in gout patients with Chronic Kidney Disease
(CKD) [43, 45]. Most of the studies considered
allopurinol-induced SJS/TEN, but only one study con-
sidered both SJS/TEN and DRESS. Five studies applied
febuxostat as an alternative drug in the model [41–45]
to patients who tested positive with HLA-B*58:01. How-
ever, probenecid has been used in Malaysia, Thailand
and Singapore [40, 46, 47] as febuxostat is not regularly
used in the usual clinical practice.
Three studies showed that HLA-B*58:01 genotyping
would be a cost-effective in China, Taiwan and Thailand
[41, 43, 47] and cost-saving intervention in the Korean
study [45]. Nevertheless, three studies from Malaysia
[40], UK [42] and Singapore [46] suggested that HLA–
B*58:01 genotyping would not be cost-effective as the
cost of the pharmacogenomics testing and alternative
drugs, such as febuxostat were too high, and the efficacy
of alternative drugs was less than that of allopurinol
(e.g., probenecid). Moreover, the study in US [44]
showed that genotyping would be cost-effective for
Asians and African Americans. However, it would not
be cost-effective for Caucasians or Hispanics. Therefore,
the incremental cost-effectiveness ratios (ICERs) might
vary substantially across racial or ethnic groups, follow-
ing by their HLA-B*5801 frequency.
HIV infection
HLA-B*57:01 and abacavir-induced hypersensitivity
reaction There were seven economic evaluation studies
of HLA-B*57:01 screening before prescribing abacavir
for HIV positive patients to prevent hypersensitivity re-
actions (HSR) that were conducted in Russia (1 study)
[48], Singapore (1 study) [49], Spain (1 study) [51],
Germany (1 study) [50], UK (1 study) [54], and US (2
studies) [52, 53] from 2004 until 2018. Most studies
were conducted in Europe and US [48, 50–54], and only
one study investigated the Asian population [49]. Results
showed that allele frequencies in Europe and US were
much higher (ranged from 3.7–7.3%) than those of the
Asian population (1.1% in Han Chinese, 1.8% in Malays),
except for Indians (3.6%). Three studies were CUA with
model-based [49, 52, 53], two studies were CEA with
model-based [51, 54] and one was CBA with model-
based economic evaluation [50]. The rest was CMA
based on a retrospective study [48]. Four studies in
Russia, Germany, UK and US demonstrated that HLA-
Table 3 Quality assessment results of evidence used based on the hierarchy of data sources by Cooper et al. [12]
Input parameters Hierarchy of data sources %
Agreement*1 2 3 4 5 6 9 #
Clinical effect sizes 16 (27%) 0 0 29 (49%) 0 2 (3%) 4 (7%) 8 (14%) 85
Baseline clinical data 4 (7%) 1 (2%) 0 51 (85%) 1 (2%) 1 (2%) 1 (2%) 81
Resource use 7 (12%) 51 (86%) 0 0 0 1 (2%) 0 92
Costs 6(10%) 53 (90%) 0 0 0 0 0 85
Utility 2(5%) 0 38 (93%) 1 (2%) 0 0 0 97
# Meta-analysis of case-control with direct comparison between comparator therapies and measuring final outcomes
*Percentage of agreement between two independent raters
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Table 4 Cost-effectiveness results of included studies











Drug: warfarin, Biomarker: CYP2C9 and VKORC1
ADRs: bleeding events












• ICER (b) vs (a): $13,562 per QALY
gained














• In UK: ICER (b) vs (a): £6702 per QALY
gained
• In Sweden: ICER (b) vs (a): 253,848 SEK
per QALY gained
3 Mitropoulou











• ICER (b) vs (a): €31,225 per QALY
gained












• Healthcare system perspective:
ICER (b) vs (a):1,477,042 THB ($49,234)
per QALY gained
• Societal perspective
ICER (b) vs (a): 1,473,852 THB ($49,128)
per QALY gained
5 You, et al., 2014
[19]
USA AF (a) warfarin




• ICER (b) vs (a): $ 2843 per QALY gained













• ICER (b) vs (a): £ 13,226 per QALY
gained
• ICER (e) vs (b): £20,671 per QALY
gained
• (d) is dominated by (c) and (e), high
cost and lower QALYs than (c) and (e)
• (c) is dominated by (e), high cost and
lower QALYs than (e)








(c) dabigatran 110mg twice daily
(d) dabigatran 150mg twice daily
$50,000 per
QALY gained
• (a) is dominated by (b), high cost and
lower QALYs than (b)
• ICER (d) vs (b): $13,810 per QALY
gained
• (c) is dominated by (d), (d) lower cost
and more effective than (c)











• ICER (b) vs (a): $ 60,725 per QALY
gained










• ICER (b) vs (a): $171,750 per QALY
gained










• ICER (b) vs (a): ICER< 50,000 per QALY
gained if it increased the time spent in
the target INR range during the first 3
months of treatment by 5 to 9
percentage points











• ICER (b) vs (a): $ 347,059 per QALY
gained






(b) CYP2C19 and VKORC1
genotyping-guided dosing of
warfarin
N/A • Low baseline bleeding: ICER (b) vs (a):
$82,890 per bleeding averted
• Medium baseline bleeding: ICER (b) vs
(a): $13,589 per bleeding averted
• High baseline bleeding: (b) is
dominated by (a) lower cost than (a)
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Table 4 Cost-effectiveness results of included studies (Continued)



















(b) CYP2C19 and VKORC1
genotyping-guided dosing of
warfarin
€20,000 • ICER (b) vs (a): € 4233 per bleeding
averted






(b) CYP2C19 and VKORC1
genotyping-guided dosing of
warfarin
N/A • ICER (b) vs (a): $5778 per bleeding
averted
Drug: clopidogrel, Biomarker: CYP2C19 ADRs: major cardiac/adverse cardiovascular events













• ICER (c) vs (a): $2560 per QALY gained
• (b) is dominated by (c), high cost and
lower QALYs than (c)






(b) prasugrel or ticagrelor
(c) CYP2C19 testing guided
therapy





• (a) is dominated by (c), high cost and
lower QALYs than (c)
• (b) is dominated by (c), high cost and
lower QALYs than (c)










(d) CYP2C19 testing guided
therapy





• ICER (d) vs (a): €81,500 per QALY
gained
• ICER (d) vs (b): €9111 per QALY gained
• ICER (d) vs (c): €5972 per QALY gained








(d) CYP2C19 testing guided
therapy





• Genotyping with prasugrel vs (a):
$35,800 per QALY gained
• Genotyping with ticagrelor vs (a):
$30,200 per QALY gained













• ICER (c) vs (a): $4200 per QALY gained
• (b) is dominated by (c), high cost and
lower QALYs than (c)













• (a) is dominated by (c), (c) lower cost
and more effective than (a)
• (b) is dominated by (c), (c) lower cost
and more effective than (b)














• ICER (c) vs (a): $AUS 6346 per QALY
gained
• ICER (b) vs (c): $AUS 22,821 per QALY
gained















• (b) is dominated by (a), high cost and
lower QALYs than (a)
• ICER (c) vs (a): $NZ 24,617 per QALY
gained
• (b) is dominated by (c), (c) lower cost
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Table 4 Cost-effectiveness results of included studies (Continued)











Test negative: clopidogrel and more effective than (b)
9 Reese E S et al.,
2012 [37]










N/A • (a) is dominated by (c), (c) lower cost
and more effective than (a)
• (b) is dominated by (c), (c) lower cost
and more effective than (b)
Drug: statin, Biomarker: pharmacogenetics test ADR: myopathy, rhabdomyolysis






with statin (only patients experi-





• (a) is dominated by (b), high cost and
lower QALYs than (b)
• (b) would be cost-effective as long as
the test costs less than CAN$906
Drug: allopurinol, Biomarker: HLAB-5801
ADR: SJS/TEN, DRESS






(a) allopurinol 100 mg and 600
mg per day
(b) febuxostat 40mgand 80mg
per day




N/A • In all 253 patients
• (c) saved 1,384,040 yuan for allopurinol
and febuxostat at the lowest dosages
• (c) saved 2,807,770 yuan for allopurinol
and febuxostat at the highest dosages
2 Chong et al.,
2018 [40]
Malaysia gout (a) allopurinol starting dose 300
mg, target dose 600mg per day
(current practice)
(b) probenecid target dose 2 g
per day







• (b) is dominated by (a), high cost and
lower QALYs than (a)
• (c) is dominated by (a), high cost and
lower QALYs than (a)
3 Jutkowitz et al.,
2017 [44]
USA gout (a) allopurinol-febuxostat sequen-
tial therapy: allopurinol:target
dose 300mg/day and febuxostat:
80 mg/day, (current practice)






• ICER (b) vs (a): for
-Asians $64,190,
-African Americans $83,450,
-Caucasians or Hispanics $183,720 per
QALY gained







(b) allopurinol target dose 100
mg/ day
(c) febuxostat 80 mg/day
(d) HLA-B5801 testing prior to
treatment








• (b) is dominated by (a), high cost and
lower QALYs than (a) current practice)
• (c) is dominated by (d), high cost and
lower QALYs than (d) current practice)
• ICER (d) vs (a): NT$ 234,610 per QALY
gained in the base-case and NT$
230,925 per QALY gained in patients
with chronic kidney disease
5 Plumpton CO
et al., 2017 [42]
UK gout (a) allopurinol target dose 300mg
per day add prophylactic
treatment with colchicine
(b) HLA-B5801 testing prior to
treatment
Test positive: febuxostat: target




• ICER (d) vs (a): £44,954 in the base case
and £38,478 per QALY in patients with
chronic renal insufficiency
6 Dong D et al.,
2015 [46]
Singapore gout (a) allopurinol starting dose 300
mg, target dose 600mg per day
(b) allopurinol +safety program
$50,000 per
QALY gained
• -ICER (b) vs (a): $79,140 per QALY
• (c) is dominated by (b), high cost and
lower QALYs than (b) current practice)
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Table 4 Cost-effectiveness results of included studies (Continued)












(c) HLA-B5801 testing prior to
treatment + SP
(d) HLA-B5801 testing prior to
treatment + SP
Test positive: probenecid target
dose 2 g per day
Test negative: allopurinol
(e) HLA-B5801 testing prior to
treatment
Test positive: probenecid target
dose 2 g per day
Test negative: allopurinol
(f) no allopurinol (treatment of
acute flares only)
• ICER (d) vs (b): $85,630 per QALY
• (e) is dominated by (d), high cost and
lower QALYs than (d) current practice)
• (f) is dominated by (d), high cost and
lower QALYs than (d) current practice)





(a) allopurinol starting dose 100
mg, target dose 300mg per day
(b) HLA-B5801 testing prior to
treatment
Test positive: febuxostat starting
dose 40 mg, target dose 80 mg)
per day
Test negative: allopurinol
N/A • Costs of (a) $1193 and (b) $1055
(b) is less costly and more effective than
(a)
8 Saokaew et al.,
2014 [47]
Thailand gout (a) allopurinol starting dose 300
mg per day
(b) HLA-B5801 testing prior to
treatment
Test positive: probenecid target




• ICER (b) vs (a): 156,937 THB per QALY
Drug: abacavir, Biomarker: HLA B*57:01
ADR: hypersensitivity
1 Kubaeva et al.,
2018 [48]
Russia HIV (a) abacavir regimen
(b) HLA-B* 5701 testing prior to
treatment
Test positive: alternative regimens
without abacavir
Test negative: abacavir regimen
N/A • (b) vs (a): was cost-saving 54,1646
rubles





HIV (a) abacavir-based ART
(b) tenofovir-based ART
(c) HLA-B:5701 testing prior to
treatment
Test positive: tenofovir-based ART
Test negative: abacavir-based ART
$50,000 per
QALY gained
• Early stage: ICER (c) vs (a):
Chinese $415,845 per QALY gained,
Malay $318,029 per QALY gained,
Indian $208,231 per QALY gained
• Late stage: ICER (c) vs (a):
Chinese $926,938 per QALY gained,
Malay $624,297 per QALY gained, Indian
$284,598 per QALY gained
• HIV who are contraindicated to
tenofovir
ICER (b) vs (a): all ethnicity was not cost-
effective, except for Indian patients with
early-stage ICER (c) vs (a): $44,649 per
QALY gained
3 Nieves Calatrava
et al., 2010 [51]
Spain HIV (a) abacavir regimen
(b) HLA-B:5701 testing prior to
treatment
Test positive: alternative HAART
regimen without ABC
Test negative: abacavir regimen
N/A • cost per HSR avoided of €630
4 Kauf TL et al.,
2010 [52]






• Short-term: (c) is dominated by (a),
high cost and lower QALYs than (a)
• Long-term: (b) is dominated by (c),
high cost and lower QALYs than (c)
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Table 4 Cost-effectiveness results of included studies (Continued)

















5 Wolf et al., 2010
[50]
Germany HIV (a) combination of abacavir+
lamivudine
(b) HLA-B:5701 testing prior to
treatment
Test positive combination of
tenofovir, emtricitabine
Test negative combination of
abacavir+ lamivudine
N/A • (b) vs (a): (b) cost-saving €44 and 127
per screened patient from healthcare
payer and societal perspective
6 Schackman BR
et al., 2008 [53]
USA HIV (a) abacavir-based regimen
(b) tenofovir-based regimen
(c) HLA-B:5701 testing prior to
treatment






• ICER (c) vs (a): $36,700 per QALY
gained
• (b) is dominated by (a),high cost and
lower QALYs than (a)
7 Hughes DA et al.,
2004 [54]
UK HIV (a) Trizivir (AZT/3TC/ABC)
(b) HLA-B:5701 testing prior to
treatment
Test positive: HAART regimen
without abacavir




N/A • (a) is dominated by (b), high cost and
lower benefit than (b), except for
Trizivir is substituted with
ritonavir+indinavir+combivir
• ICER (b) vs (a): € 22,811 per
hypersensitivity reaction avoided
Drug: efavirenz, Biomarker: CYP2B6, ADRs: sub- or supratherapeutically dosed
1 Schackman et al.,
2015 [55]
USA HIV (a) efavirenz 600 mg + tenofovir+
emtricitabine
(b) CYP 2B6 testing prior to
treatment
Test positive: decrease dose to
200,400 mg
Test negative: efavirenz 600 mg
(c) Universal low dose efavirenz
400 mg + tenofovir+ emtricitabine
$ < 100,000 per
QALY gained
• (a) is dominated by (b), high cost and
lower benefit than (b)
Drug: azathioprine, Biomarker: TPMT ADR: neutropenia or severe neutropenia
1 Thompson AJ











• (b) is dominated by (a) lower cost and
lower QALYs than (a)








(b) TPMT testing prior to
treatment (Phenotype and
genotype)
N/A • Phenotype and genotype testing
dominated by (a), high cost and lower
QALYs than (a) There are cost-savings
(vs no testing) of $NZ120,000 and 71
neutropenias avoided;-034QALYs and
$NZ11,000 and 40 neutropenias
avoided, −058QALYs)
Drug: azathioprine, Biomarker: TPMT ADR: leukopenia





(a) conservative therapy which no
specific therapy
(b) azathioprine+N-acetylcysteine
and steroids (no testing)
(c) TPMT testing prior to
$50,000 per
QALY gained
• ICER (b) vs (a): $49,245 per QALY
*ICER (c) vs (b): $29,663 per QALY
gained
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Table 4 Cost-effectiveness results of included studies (Continued)

















et al., 2005 [60]
USA Crohn’s
disease




(b) metabolite monitoring (MM)
prior to treatment with
azathioprin
(c) TPMT testing +MM prior to
treatment with azathioprine
(d) community care (CC)
N/A • (d) is dominated by (a), (b),and (c), (d)
less costs and faster time to response
or sustained response
5 Winter J et al.,
2004 [61]
Scotland IBD (a) azathioprine
(b) TPMT testing prior to
treatment
N/A • for a 30 year old: ICER (b) vs (a): £347
per life-year saved and
• for a 60 year old: ICER (b) vs (a): £817
per life-year saved
Drug: azathioprine, Biomarker: TPMT ADR: all adverse events






(b) TPMT testing prior to
treatment
N/A • The direct health care costs for (a)
$30,011 per patient and (b) $34,887
per patient
Drug: azathioprine, Biomarker: TPMT ADR: severe bone marrow toxicity







(b) TPMT testing prior to
treatment
N/A • (a) is dominated by (b), (b) lower cost
and more effective than (a)
Drug: azathioprine, Biomarker: TPMT ADR: hematological cytopenias







(b) TPMT testing prior to
treatment
N/A • (a) cost $677 Cdn per patient, (b) cost
$663 Cdn per patient
Drug: carbamazepine, Biomarker: HLAA*15:02, ADRs: SJS, TENs, hypersensitivity
1 Chong et al.,
2017 [64]
Malaysia Epilepsy (a) carbamazepine (current
practice)
(b) sodium valproate (VPA)







• (b) is dominated by (a), high cost and
lower QALYs than (a) current practice)
• (c) is dominated by (a), high cost and
lower QALYs than (a) current practice)
2 Chen et al., 2016
[65]
Hong Kong Epilepsy (a) current situation, using
antiepileptic drug (pre-policy
period)
(b) current situation, using
antiepileptic drug (post-policy
period)
(c) HLA-B*15:02 testing prior to
treatment (the ideal situation)
(ideal situation)
Test positive: alternative anti-
epileptic drug
Test negative: carbamazepine or
phenytoin
(d) HLA-B*15:02 testing prior to




• ICER (b) vs (a): $85,697 per QALY
gained
• ICER (c) vs (a): $11,090 per QALY
gained
• ICER (d) vs (a): $197,158 per QALY
gained
3 Rattanavipapong





(a) carbamazepine (no HLA-B*15:
02 testing)
(b) HLA-B*15:02 testing prior to
120,000 THB per
QALY gained
• ICER (b) vs (a):
222,000 THB per QALY for epilepsy,
130,000 THB per QALY for neuropathic
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for epilepsy: valproate, for
neuropathic pain: gabapentin;
Test negative: carbamazepine





• ICER (c) vs (a):
32,522,000 per QALY for epilepsy,
(epilepsy), 35,877,000 per QALY for
neuropathic pain












N/A • (b) vs (a): (b) was cost-saving 98,54,994
THB per 100 cases of carbamazepine
users
5 Dong D et al.,
2012 [68]
Singapore Epilepsy (a) carbamazepine or phenytoin
(b) HLA-B*15:02 testing prior to
treatment
Test positive: valproate;
Test negative carbamazepine or
phenytoin
(c) valproate (no screening)
$50,000 per
QALY gained
ICER (b) vs (a):
Chinese patients $37,030 per QALY
gained, Malay $7930 per QALY gained
and Indians $136,630 per QALY gained
• (c) is dominated by (b), high cost and
lower QALYs than (b)
Drug: carbamazepine, Biomarker: HLAA*31:01, ADRs: SJS, TENs, hypersensitivity
1 Plumpton et al.,
2015 [69]
UK Epilepsy (a) carbamazepine






• ICER (b) vs (a): £ 12,808 per QALY
gained
Drug: Fluoropyrimidines, Biomarker: DPYD*2A genotype–guided dosing ADR: toxicity iehematologic, GI






(b) DPYD*2A testing prior to
treatment
Test positive: alternative regimen
Test negative: Fluoropyrimidines-
based
N/A • (b) vs (a): (b) cost-savings of €45 ($61)
per patient
Drug: irinotecan, Biomarker: UGT1A1 ADR: severe neutropenia





(a) FOLFIRI regimen (5-
fluorouracil, leucovorin and
irinotecan)
(b) UGT1A1 testing prior to
treatment with FOLFIRI
Test positive: FOLFOX regimen
(oxaliplatine + 5-FU + folinic acid)
Test negative: FOLFIRI
N/A • ICER (b) vs (a): to avoid one febrile
neutropenia per 1000 patients treated
was € 9428 to € 10,901





(a) FOLFIRI regimen (5-
fluorouracil, leucovorin and
irinotecan)
(b) UGT1A1 testing prior to
treatment with FOLFIRI





• ICER (b) vs (a): was cost-effective if the
treatment efficacy of irinotecan in ho-
mozygotes after dose reduction had to
be ≥984% of full-dose efficacy for gen-
etic testing to remain preferred
Drug: nortriptyline, Biomarker: CYP2D6 ADRs: sub- or supratherapeutic dose












• ICER (b) vs (a): €1,333,000 per QALY
gained
Drug: oral contraceptive, Biomarker: factor V Leiden ADR: Thromboembolism








• ICER (d) vs (c): $ 147 per QALY gained
• ICER (e) vs (d): $ 639,500 per QALY
Turongkaravee et al. BMC Health Services Research         (2021) 21:1042 Page 15 of 23
B*57:01 testing would be cost-effective [53, 54] and cost-
saving [48, 50] to prevent HSR due to abacavir as com-
pared with no testing, while the remaining studies
showed that it was not cost-effective [51, 52]. In
addition, the study in Singapore [48] suggested that
genotyping was not cost-effective for Han Chinese and
Malays ethnicity but cost-effective in Indian patients.
This was because the frequency of the HLA-B*5701 al-
lele and positive predictive value (PPV) in Indians were
higher than in Han Chinese and Malays.
CYP2B6 and efavirenz-induced CNS toxicity The
study in US demonstrated that the CYP2B6 genotyping
before prescribing efavirenz to prevent central nervous
system (CNS) toxicity in HIV patients was cost-saving as
compared with no testing due to a lower lifetime cost
and a gain in QALYs [55].
Autoimmune diseases
TPMT and azathioprine-induced severe bone marrow
toxicity Azathioprine-induced severe bone marrow tox-
icity was associated with TPMT in patients with auto-
immune diseases, inflammatory bowel disease, idiopathic
pulmonary fibrosis (IPF), Crohn’s disease, rheumatoid
arthritis or systemic lupus erythematous. Eight studies
were carried out in UK (1 study) [56], New Zealand (1
study) [58], Scotland (1 study) [61], Korea (1 study) [62],
Canada (2 studies) [59, 63], and US (2 studies) [57, 60]
from 2002 to 2014. These studies employed CUA with
model-based (2 studies), [57, 58] CUA with trial-based
(1 study) [56], CEA with model-based (2 studies), [60,
62] CEA with trial-based (1 study) [61], CBA with
model-based (1 study) [63], and CMA with a random-
ized prospective study (1 study) [59]. Five studies
showed that testing would be a cost-effective [57, 60–
62] and cost-saving intervention [63] to prevent severe
ADRs regarding azathioprine as compared with no test-
ing. Nevertheless, two studies from UK [56] and New
Zeland [58] suggested that genotyping would not be
cost-effective due to higher costs and lower QALYs than
azathioprine therapy without testing. In Canada, it was
discovered that genetic testing was not cost-saving [59].
Epilepsy/neuropathic pain
HLA-B*15:02 and carbamazepine-induced SJS/TEN
Five economic evaluation studies of HLA-B*15:02 geno-
typing to prevent the risk of SJS/TEN in patients pre-
scribed carbamazepine (CBZ) were carried out in
Malaysia [64], Hong Kong [65], Thailand (2 studies) [66,
67] and Singapore [68] from 2012 to 2017. Four studies
applied CUA with model-based economic evaluation
[64, 65, 67, 68], while the other study used CBA with
retrospective study [66]. All studies focused on the pa-
tients diagnosed with epilepsy. Only the study from
Thailand [67] included both patients with epilepsy and
neuropathic pain. Moreover, the study from Singapore
[68] was performed separately for the major ethnic
groups, which were Han Chinese, Malays and Indians.
Three studies used valproate [64, 67, 68], while the rest
of the studies used any anti-epileptic drug as an alterna-
tive for those patients who tested positive with HLA-
B*15:02 [65, 66].
The findings from three studies showed that a testing
would be cost-effective [65, 68] and cost-saving to pre-
vent SJS/TEN in CBZ, as compared with no testing [66].
However, a study in Malaysia indicated that testing
would not be cost-effective as a result of ethnicity and
an effective alternative drug for those who tested positive
[64]. The study in Thailand showed that HLA-B*15:02
screening would be cost-effective in CBZ-treated pa-
tients with neuropathic pain but not for epilepsy because
the cost of alternative drugs for epilepsy was approxi-
mately two times higher than the cost for neuropathic
pain [67].
HLA-A*31:01 and carbamazepine-induced SJS/TEN
and hypersensitivity Notably, CBZ has been associated
with HLA-A*31:01 and it can lead to severe ADRs, such
as SJS/TEN and hypersensitivity. A study in UK was per-
formed using CUA with model-based economic
Table 4 Cost-effectiveness results of included studies (Continued)













(c) genotyping with OCP
counseling
(d) genotyping with OCP
counseling and AC for high-risk
events
(e) genotyping with OCP
counseling and AC for long-term
• (a) is dominated by (d), high cost and
lower QALYs than (d)
• (b) is dominated by (d), high cost and
lower QALYs than (d))
AC: anticoagulation, ACS: Acute Coronary Syndrome, CBA: Cost-benefit analysis, CEA: Cost-effectiveness analysis, CMA: Cost-minimization analysis, CUA: Cost-
utility analysis, EE: Economic evaluation, ICER: Incremental Cost-Effectiveness Ratio
OCP: oral contraceptive pill, PCI: Percutaneous Coronary Intervention, PSA: Probabilistic Sensitivity Analysis
QALY: Quality adjusted life-year, N/A: Not Applicable, WTP: Willingness to pay
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evaluation in 2015. The results showed that testing
would be cost-effective as the efficacy (e.g., remission
rate) of anti-epileptic drugs was the main driver of cost-
effectiveness results [69]. In addition, this study used
lamotrigine as an alternative drug for patients who
tested positive rather than valproate, which might be dif-
ferent from other clinical settings.
Cancer
UGT1A1 and irinotecan-induced severe neutropenia
One CUA with model-based study from France [71] and
one CEA with model-based study from the US [72] were
performed to evaluate the cost-effectiveness of UGT1A1
screening before prescribing irinotecan to prevent severe
neutropenia in metastatic colorectal cancer. The results
demonstrated that genotyping would be a cost-effective
intervention.
DPYD and fluoropyrimidines-induced severe
hematologic and GI toxicity One study was conducted
in the Netherlands [70] using CBA with model-based
economic evaluation in 2016. The results demonstrated
that DPYD testing before prescription of fluoropyrimi-
dines would be cost-saving, as compared with no testing,
in preventing severe hematologic and GI toxicity due to
fluoropyrimidine.
Major depressive disorder
CYP2D6 and nortriptyline-induced anticholinergic
symptoms The CUA with model-based economic evalu-
ation in the Netherland study showed that CYP2D6
screening for adjusting dose before starting nortriptyline
compared to no screening would not be cost-effective
since CYP2D6 was not potentially related to the reduc-
tion of ADRs and to the increased efficacy of nortripty-
line in a major depressive disorder [73].
Hormone replacement therapy
Factor V Leiden and estrogen combined in oral
contraceptives-induced thromboembolism The CUA
with model-based study in US was conducted to evaluate
the cost-effectiveness of Factor V Leiden testing before a
prescription of estrogen-containing oral contraceptives
to avoid thromboembolism. The study compared testing
before prescribing the drug, testing with oral contracep-
tive pill (OCP) counselling, testing with OCP counselling
and anticoagulation (AC) with the usual care without
testing. The results demonstrated that testing with OCP
counselling and prophylactic AC during high-risk pe-
riods in female relatives of FVL carriers was cost-
effective [74].
Uncertainty analysis results
Based on the results of uncertainty analysis from the in-
cluded studies, parameters which could influence the
cost-effectiveness results are summarized in terms of
therapeutic areas and gene-drug pairs in Table 5. These
parameters were classified into three types: (1) epidemio-
logical and disease progression parameters, e.g., prob-
ability of ADRs related to drug treatment, allele
frequency, PPV or negative predictive value (NPV), and
mortality rate of ADRs, (2) clinical effectiveness data,
e.g., the efficacy of genetic testing and drugs treatment,
and (3) resource use and cost parameters, e.g., costs of
genetic testing, alternative drugs and hospitalization.
Our review indicated that cost-effectiveness results
were mostly sensitive to the probability of drug induced-
ADRs, the effectiveness of pharmacogenetic testing to
prevent ADRs, the cost of testing, and the cost of alter-
native drugs in patients who tested positive. For in-
stance, in cardiovascular diseases, the probability of
MACE due to clopidogrel and the efficacy of CYP2C9
and VKORC1 testing to avoid bleeding complications of
warfarin mostly affected the ICER results in clopidogrel
and warfarin users, respectively. Furthermore, for HIV
infection, the cost of testing had an impact on the ICER
results in both abacavir and efavirenz. However, there
was no reported uncertainty analysis from a one-way
sensitivity analysis among these studies [18, 20, 32, 37,
41, 48, 59, 61, 66, 74].
The transferability of economic evaluation results
Based on Welte et al’s method [15] that assesses the
transferability of economic evaluation results across
countries, three transferability factors were determined
from the economic evaluations for HLAB*5801-allopur-
inol in gout patients [40–47] as a case study. First, meth-
odological characteristics, e.g., perspective, time horizon,
cost categories, and discount rate used, varied across
CUA studies. Among six CUA studies, a healthcare
payer perspective was the most common, followed by a
societal perspective. Nevertheless, lifetime horizon was
mostly applied. Cost categories and discount rates used
were different. Although three main direct medication
costs, e.g., the cost of HLAB*5801 testing, cost of treat-
ing ADRs and cost of gout maintenance treatment, were
mostly included, the cost of flare management of an
acute flare or death was considered in some studies.
Based on a societal perspective, direct non-medical cost,
e.g., transportation cost and additional food cost for pa-
tients and their relatives, and indirect costs, e.g., prod-
uctivity loss due to illness, were incorporated. Costs and
outcomes were discounted at a rate of 3% or 3.5%.
Secondly, the healthcare system characteristics in a
particular practice varied among countries. It was re-
ported that China, Taiwan, Korea, UK and US applied
Turongkaravee et al. BMC Health Services Research         (2021) 21:1042 Page 17 of 23
febuxostat as an alternative drug in the model based on
the recommendations of the American College of
Rheumatology that allopurinol and febuxostat were first-
line agents for the management of gout [77, 78]. How-
ever, febuxostat is not regularly used as an alternative
drug in the general clinical practice in Malaysia,
Thailand and Singapore. Although the same alternative
drug was used, the dosage differed across studies. For in-
stance, allopurinol was used starting at either 100 to
600 mg/day or 100 to 300 mg/day in patients with CKD,
febuxostat was used at 40 to 80mg/day, and probenecid
was used at 2 g/day.
Lastly, in terms of population characteristics, disease
prevalence was one of the substantial variation factors
that could not be transferred from one country to an-
other. The HLA-B*5801 allele frequency and PPV for
SJS/TEN were the key drivers influencing cost-
effectiveness results. Interestingly, the study in US
revealed that genotyping would be cost-effective for
Asians and African Americans but not for Caucasians or
Hispanics because the HLA-B*5801 frequency was varied
substantially across racial or ethnic groups which had an
impact on the ICERs [44]. Indeed, the HLA-B*5801 allele
frequency ranged from 11.9–18.5% in Asian studies [40,
41, 43, 45–47] and was higher than in US and Europe
[42, 44], which ranged from 0.7–3.8%.
Furthermore, the PPV in the Asians was higher
than in American and European populations. This im-
plied that Asians who carried HLA-B*5801 allele
would have more chances to develop SJS/TEN as
compared with Americans and Europeans. In sum-
mary, regarding the differences in three potential
transferability factors across countries, the cost-
effectiveness results would be useful for a context
specific setting as they may not be directly transferred
from one country to another.
Table 5 Number of studies reporting parameters which could influence the cost-effectiveness results
Therapeutic area Epidemiological and disease progression
parameters























Cardiovascular disease (n = 24)
CYP2C19 -Clopidogrel [30, 33, 34] [31] [35] [36] [38]
CYP2C9 and VKORC1
-Warfarin






Gout (n = 8)
HLA-B*58:01 -Allopurinol [43, 44, 46] [45] [40] [42] [44] [40, 47]
HIV infection (n = 8)
HLA-B*57:01 -Abacavir [50] [49] [51, 52] [53, 54]
CYP2B6 -Efavirenz [55]
Autoimmune disease (n = 8)
TPMT - Azathioprine [57] [62] [63] [56, 58] [60]





[64, 69] [65, 67]
Cancer (n = 3)
UGT1A1 -Irinotecan [71] [72]
DPYD -Fluoropyrimidine [70]
Major depressive disorder (n = 1)
CYP2D6 -Nortriptyline [73] [73]




ADRs: Adverse Drug Reactions, PPV: Positive Predictive Value, NPV: Negative Predictive Value
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Discussion
Our study provided the most updated systematic review
on economic evaluation studies of pharmacogenetic test-
ing for prevention of ADRs (59 studies) as compared
with two previously published systematic reviews in
2008 (7 studies) and 2016 (47 studies). The majority of
included studies were conducted in cardiovascular dis-
eases and mostly found in Europe and US; whereas, only
one-third of them were performed in Asian countries.
Given the fact that the frequency of each genotyping
was different across countries, the cost-effectiveness of
pharmacogenetic testing would depend on the ethnicity
of patients who were receiving the tests. For instance,
HLA-B*15:02 allele is more frequent among Asians than
Caucasians, while HLA-A*31:01 is rarer in Asians, but
more frequent in Caucasians. Therefore, the regular
screening before starting carbamazepine therapy for
HLA-B*15:02 in Asians is more useful than HLA-A*31:
01 in the context of clinical implementation and future
economic evaluation study. Alongside this, pharmacoge-
netic testing can prevent drug-induced severe ADRs on
clinical outcomes and reduce economic burden, which
are considered significant impacts involving the interest
of policy-makers and healthcare professionals [2, 4].
Compared with previous published reviews, we included
additional economic evaluation studies of other pharma-
cogenetic testing, such as CYP2D6-nortriptyline,
CYP2B6-efavirenz, DPYD- fluoropyrimidines and
UGT1A1- irinotecan, and statins.
Our review suggested that CUA and CEA were the
most common methods for performing the economic
evaluation of pharmacogenetic testing. This is consistent
with the recommendation by Col NF et al. [79] and
Payne K et al. [80], denoting that economic evaluation
methods, i.e., CUA or CEA could capture all relevant
costs and benefits of pharmacogenetics testing [79, 80].
In addition, our review on cost-effectiveness results of
the pharmacogenetic testing for prevention of ADRs
showed differences in the parameters, methods and out-
comes among included studies. Consequently, this raised
concerns on the transferability of the cost-effectiveness
analysis results from one country to another, which has
been increasingly recognized due to healthcare resource
constraints [15].
Notably, our systematic review shed light on the crit-
ical appraisal of all included studies to evaluate the qual-
ity in terms of reporting and the source of evidence used
for important model input parameters, which had sig-
nificant impact on cost-effectiveness results. Based on
the quality appraisal on reporting economic evaluations
according to the CHEERS checklist [14], most studies
complied with the checklist, except for single study-
based economic evaluations. The finding highlighted
that 78% of the single study-based economic evaluation
studies did not report uncertainty analysis results of the
parameters affecting cost-effectiveness results. This may
be due to the fact that these reports did not indicate
confidence intervals which are necessary measures for
performing uncertainty analysis. It should be noted that
the advantages of the uncertainty analysis surrounding
effects and costs are to provide a correct evaluation of
the expected effects and costs, to consider whether exist-
ing evidence is sufficient, and to assess the possible con-
sequences of an uncertain decision for decision makers
[81]. Therefore, it is worth noting that future studies on
the economic evaluation of pharmacogenetic testing
with single study-based studies should include uncer-
tainty analysis, since this could significantly lead to the
robustness of economic evaluation results. Furthermore,
our study revealed that there were studies that failed to
report funding (20%) and authors’ disclosure of conflicts
of interest (COI) (22%), possibly leading to biased results
when making decisions by clinicians, patients and
policy-makers, as the authors or funders might have in-
fluenced the research findings. Most studies with the
omissions of funding sources (67%) and COI (85%) were
published between 2002 to 2010, when the reporting of
this information had not been mandatory by the journal
standards.
In addition, our review highlighted two gaps of know-
ledge that should be considered for assessing the quality
of data sources used for pharmacogenetic testing. First,
data sources of clinical effectiveness in several thera-
peutic areas related to pharmacogenetic testing to pre-
vent drug-induced serious ADRs were very limited,
which was consistent with the previous review [11].
Nevertheless, we appraised broader data sources of evi-
dence used not only clinical effectiveness data, but also
baseline clinical values, costs as well as resources used
and utility data. Our results revealed that there was lack
of high-quality evidence, not only estimating the clinical
effectiveness of pharmacogenetic testing, but also pro-
viding baseline clinical data, according to the hier-
archy of evidence developed by Cooper et al. [12].
For example, only 16 studies (27%) obtained clinical
effectiveness data of genetic testing from five major
RCTs: the PREDICT-1 trial [82] for HLA-B*57:01-aba-
cavir, the TARGET trial [83] for TPMT-azathioprine,
ARIES trial [84] and the COUMAGEN trial [85] for
CYP2C9 and VKORC1-warfarin, the PLATO trial [86,
87] for CYP2C19-clopidogrel. Yet, of all RCTs, only
two RCTs supported pharmacogenetic testing to pre-
vent severe ADRs induced by abacavir and azathio-
prine. Interestingly, we found that eight studies (14%)
obtained clinical effectiveness of testing from the
meta-analysis of case-control study with direct com-
parison, which is not listed in the hierarchy of data
sources by Cooper et al. [12].
Turongkaravee et al. BMC Health Services Research         (2021) 21:1042 Page 19 of 23
Second, there were very limited baseline clinical
data on pharmacogenetic testing. Our review revealed
that only five studies (9%) explicitly analyzed baseline
clinical data from reliable databases, including pa-
tients from the study setting given that such specific
database included patients who developed severe
ADRs, which are rare events that might not be com-
monly available. It should be noted that the quality of
sources, especially for clinical effectiveness and base-
line clinical data, used to evaluate the economic eval-
uations of pharmacogenetic testing would be relatively
different from that of pharmaceutical interventions.
Consequently, this could shed light on a specific
ranking system for quality of evidence which is
needed for economic evaluation of pharmacogenetic
testing to prevent ADRs.
Our study had several strengths. First, pharmacoge-
netic testing and drug-related ADRs were selected based
on the list of currently available clinical guidelines and
approved drug labels. Thus, only studies related to treat-
ment options in clinical practice were included to ensure
a significant benefit of pharmacogenetic testing and
might be useful for clinical decision-making and policy
implementation. Second, we added several pharmacoge-
netic testing from previous studies, such as CYP2D6-
nortriptyline, CYP2B6-efavirenz, DPYD-fluoropyrimi-
dines, UGT1A1- irinotecan, and pharmacogenetic testing
for statins. Third, we appraised the quality of included
studies for both the quality of reporting and data sources
of evidence used which had a broader component than
the previous studies. This review also described in detail
the differences in parameters, methods and economic
evaluation results of included studies. Furthermore, we
demonstrated a case study to evaluate the transferability
of the study results across countries according to poten-
tial transferability factors to inform that the economic
evaluations of pharmacogenetic testing would be useful
for a specific setting or might not been transferred to
other clinical settings. The above hypotheses have been
supported by the clearly established evidence demon-
strating that race/ethnicity and geographic region were
possible influencers on the prevalence of HLA-B*5801,
in which the prevalence of HLA-B*5801 (< 1%) was
found to be lower in Caucasians and Hispanics than that
in African Americans (3.8%) and Asians (7.4%) [1, 14].
It is significant to address some limitations in our
study. First, we evaluated the quality of data sources for
model input parameters from the only existing published
criteria for economic evaluation study developed by
Cooper et al. and the quality of reporting using the
CHEERS checklist guidelines. However, the ranking of
data sources may not be specific to the economic evalua-
tions of pharmacogenetic testing. To the best of our
knowledge, there have been existing published guidelines
of the International Society for Pharmacoeconomics and
Outcomes Research relevant to this topic [88–92], in
which we did not apply them to our study. It is recom-
mended that those guidelines could be used as criteria in
future studies. Second, some studies did not report un-
certainty analysis results, which could affect cost-
effectiveness results, therefore we could consider only
the results of one-way sensitivity analysis obtained from
included studies.
Conclusions
This comprehensive review found fifty-nine economic
evaluations of pharmacogenetic testing to avoid drug-
induced severe ADRs, which mostly focused on thera-
peutic areas of cardiovascular diseases. CUA and CEA
were commonly applied to perform the economic
evaluation of pharmacogenetic testing to prevent drug-
induced ADRs. Based on the quality appraisal on report-
ing economic evaluations according to the CHEERS
checklist guidelines [14], most studies complied with the
guidelines, except that uncertainty analysis of single
study-based economic evaluations should be reported.
The quality of evidence used in clinical effectiveness data
and the baseline clinical data were considered to be low-
quality according to the hierarchy of evidence proposed
by Cooper et al. Therefore, the criteria for assessing the
quality of evidence used for economic evaluation of
pharmacogenetic testing of ADRs are needed to be fur-
ther developed. Differences in parameters, methods and
outcomes across studies as well as population-level and
system-level differences may lead to the difficulty of
comparing cost-effectiveness results across countries.
Our findings might be useful for developing future and
robust cost-effectiveness analyses of pharmacogenetic
testing to inform policy-makers on how to allocate re-
sources effectively and implement such testing into clin-
ical practice.
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